



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/719,554	01/18/2001	Patrick M. Alliel	200936USPCT	1650

22850 7590 08/05/2002

OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC  
FOURTH FLOOR  
1755 JEFFERSON DAVIS HIGHWAY  
ARLINGTON, VA 22202

EXAMINER

BROWN, STACY S

ART UNIT	PAPER NUMBER
----------	--------------

1648

DATE MAILED: 08/05/2002

10

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/719,554

Applicant(s)

ALLIEL ET AL.

Examiner

Stacy S Brown

Art Unit

1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 18 July 2002.
- 2a) ☐ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-37 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-37 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                             | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____  |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)         | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____                                    |

### DETAILED ACTION

1. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to **Group Art Unit 1648**.
2. Applicant's preliminary amendment, received July 15, 2002, is acknowledged and entered. Claims 1-37 are pending.

### *Election/Restrictions*

3. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- Group I, claims 1 and 33, drawn to a nucleic acid fragment and vector comprising SEQ ID NO: 1 (*env*).
- Group II, claim 2, drawn to a nucleic acid fragment comprising SEQ ID NOS: 1 and 2 (*env* and *gag*).
- Group III, claim 3, drawn to a nucleic acid fragment comprising SEQ ID NOS: 1, 3-22, 28 and 61 (*env* and unknown). If Applicant intended to claim SEQ ID NO: 1 and one of SEQ ID NOS: 3-22, 28 and 61, then SEQ ID NO: 1 will be searched along with one elected sequence from SEQ ID NOS: 3-22, 28 and 61.
- Group IV, claim 4, drawn to transcripts generated from nucleic acid.

Art Unit: 1648

- Group V, claims 5-9, drawn to a diagnostic reagent having retroviral motifs comprising SEQ ID NO: 1-22, 28, 37-57, 59-61 and 121-122. Applicant must **elect one sequence** for examination.
- Group VI, claims 10 and 12, drawn to a method for detection of nucleic sequences of *env*. Applicant must **elect one sequence** for examination.
- Group VII, claim 11, drawn to a method for detection of nucleic sequences of *env* and *gag*. Applicant must **elect one sequence** for examination.
- Group VIII, claim 13, drawn to chimeric sequences.
- Group IX, claims 14-16, drawn to a method for detection/evaluation of overexpression/underexpression/modification of an HERV-7q type sequence. Applicant must **elect one sequence** for examination.
- Group X, claims 17-18, drawn to a kit for detecting autoimmune disease. Applicant must **elect one sequence** for examination.
- Group XI, claim 19, drawn to translational products.
- Group XII, claims 20-26 and 34, drawn to a peptide. Applicant must **elect one nucleic acid sequence and one amino acid sequence** for examination.
- Group XIII, claims 27 and 28, drawn to an antibody. Applicant must **elect one amino acid sequence** for examination.
- Group XIV, claim 29, drawn to a method for differential immunological screening of retroviral sequences. Applicant must **elect one amino acid sequence** for examination.

Art Unit: 1648

- Group XV, claim 30, drawn to a method for identification of endogenous retroviral motifs associated with cancer or neuropathological conditions. Applicant must elect either cancer or neuropathological conditions.
- Group XVI, claim 31, drawn to an application of the SEQ ID NO: 1 for the detection, prognosis and evaluation of genetic susceptibility to cancer, autoimmune and/or neurological components. Applicant must elect either cancer or neurological disease. (Autoimmune disease will be grouped with neurological disease.)
- Group XVII, claim 32, drawn to hybrid nucleic acid sequences.
- Group XVIII, claims 35-36, drawn to a gene therapy vector comprising SEQ ID NO: 1. Applicant must **elect one sequence** for examination.
- Group XIX, claim 37, drawn to transgenic animals. Applicant must **elect one sequence** for examination.

The inventions listed as Groups I-XXI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Claim 1, Group I, is drawn to a nucleic acid fragment comprising SEQ ID NO: 1. This sequence was known at the time of Applicant's invention, see attachment. Therefore, since Group I is anticipated by the prior art, there is no special technical feature linking the groups of inventions together.

The inventions are distinct, each from the other because of the following reasons:

a) Restriction between sequences is required in Groups III, V-VII, IX, X, XII-XIV, XVIII and XIX. The nucleic acid sequences are distinct from each other because they have different

Art Unit: 1648

lengths, nucleic acids, and encode different products. The amino acids are distinct from each other because they have different lengths and structures.

b) Groups I-V, VIII, X-XIII and XVI-XIX are all distinct products drawn to different nucleic acids, transcripts generated from the nucleic acids, diagnostics having different sequences, kits for detecting autoimmune disease, translational products, peptides encoded by the nucleic acids, immunogenic compositions and vaccines, antibodies, and transgenic animals. Groups I-III are distinct because they have different nucleic acid sequences encoding different products. The nucleic acids and amino acids/peptides are distinct products because they have different structures and functions. The peptides and antibodies are distinct because they have different structures, functions, modes of operation and effect. The gene therapy vector is distinct from the other nucleic acids because it comprises different sequences. The transgenic animals are distinct from the nucleic acids, proteins, peptides and antibodies because they are not disclosed as capable of use together. In summary, the products claimed do not share the same functions, structures, modes of operation and effects, and are therefore distinct products that are not disclosed as capable of use together.

c) Inventions (I-IV, X-XII and XVI-XIX) and (VI-VII, IX and XIV-XV) are unrelated. The nucleic acids, transcripts, kit for detecting autoimmune disease, translational products, peptide, hybrid nucleic acid sequences, vector and transgenic animals are not required to practice the methods of detecting nucleic acids, screening retroviral sequences or identifying retroviral motifs.

d) Inventions V and (VI-VII) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using

Art Unit: 1648

the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product, comprising nucleic acids, can be used in a materially different method of using, such as inducing an immune response.

e) Inventions V and (IX, XIV and XV) are unrelated. The diagnostic reagent of Group V is not required to practice the methods of detecting sequences, screening sequences or identifying motifs.

f) Inventions VI and VII are distinct inventions because they require different sequences to practice the method, resulting in a different mode of operation, function and effect.

g) Inventions (VI-VII) and (VIII, IX and XVIII-XV) are unrelated inventions. The method of detecting nucleic acid sequences is not required to practice the other methods claimed. They have different method steps, reagents and functions.

h) Inventions VIII and IX are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the chimeric sequences can be used in a materially different method of using such as inducing an immune response.

i) Inventions (VIII-XII) and (XIV-XV) are unrelated inventions. The chimeric sequences, translational products, peptides, kits for detecting autoimmune disease and method for detecting sequences are not required to practice the methods of Groups XIV and XV.

Art Unit: 1648

j) Inventions XIII and (XIV and XV) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the antibodies can be used in a materially different process of using, such as inducing an immune response.

k) Inventions XIV and XV are distinct methods having different method steps, modes of operation, function and effect. The methods are not disclosed as capable of use together.

l) Restriction between cancer and neurological disease is required because the diseases are unrelated and would require further searching. Methods or products for detecting cancer and neurological diseases encompass different searches that are not co-extensive.

Because these inventions are distinct for the reasons given above and the sequence search and literature search required for one group is not required or not co-extensive for any other group, and therefore burdensome, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).




*Conclusion*

Papers relating to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 located in Crystal Mall 1. The Fax number for Art Unit 1648 is (703) 308-4426. All Group 1600 Fax machines will be available to receive transmissions 24 hrs/day, 7 days/wk. Please note that the faxing of such papers must conform with the Notice published in the Official Gazette, 1096 OG 30, (November 15, 1989).

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Stacy S. Brown, whose telephone number is (703) 308-2361. The Examiner can normally be reached on Monday through Friday and alternate Wednesdays from 6:30 AM-4:00 PM, (EST). If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, James C. Housel, can be reached at (703) 308-4027. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Stacy S. Brown  
August 2, 2002



HANKYEL T. PARK, PH.D  
PRIMARY EXAMINER

RESULT 4  
LOCUS HSAC000064 56093 bp DNA linear PRI 13-NOV-1996  
DEFINITION Human BAC clone RG083M05 from 7q21-7q22, complete sequence.  
AC000064  
AC000064.1 GI:1669369  
KEYWORDS HTG.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 56093)  
AUTHORS Pauley, A.  
JOURNAL The sequence of H. sapiens BAC clone RG083M05  
REFERENCE 2 (bases 1 to 56093)  
AUTHORS Waterston, R.  
JOURNAL Direct Submission  
COMMENT Submitted (13-NOV-1996)  
Genome Sequencing Center  
Department of Genetics, Washington University  
St. Louis, MO 63108, USA  
e-mail: sapiens@watson.wustl.edu

NOTICE: This sequence may not represent the entire insert of this clone. It may be shorter because we only sequence overlapping sections once, or longer because we provide a small overlap between neighboring submissions.

This sequence was finished as follows unless otherwise noted:  
all regions were double stranded or sequenced with an alternate chemistry; an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by sequence from more than one subclone; and the assembly was confirmed by restriction digest.

SOURCE INFORMATION:

This clone is from the first release of the human BAC library. The library contains cloned DNA from a human male fibroblast cell line 978SK. For references see: Shizuya et al., Proc. Natl. Acad. Sci. 89:8794-8797 (1992); Kim et al., Genomics 34:213-218 (1996).  
VECTOR: pBE10  
Selection: chloramphenicol

NEIGHBORING SEQUENCE INFORMATION:

The orientation of this clone is unknown. Actual start of this clone is at base position 1 of H\_RG083M05; actual end is at 56093 of H\_RG083M05

FEATURES

source  
1..56093  
Location/Qualifiers  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="7"  
/map="7q21-7q22"  
/clone="H\_RG083M05"  
/clone\_1lb="CIRB-978SK-B"  
repeat\_region  
complement(838..1131)

gene  
CDS  
/rpt\_family="ALU"  
<1360..16971  
/gene="WUGSC:H\_RG083M05.1"  
join(<1360..1503,4181..4370,4587..4774,6422..6556,  
9483..9547,11631..11773,11864..12021,13131..13296,  
14885..14988,16349..16546,16837..16971)  
/gene="WUGSC:H\_RG083M05.1"  
/note="Appase; strong similarity to peroxisome  
biosynthesis protein PAB1 (PID:g1172019); coded for by  
human cDNA C04279 (NID:g1467530)"  
/codon\_start=1  
/protein\_id="AAB46346.1"  
/db\_xref="GI:1669371"

/translation="KRLENQKLEVAFAFPAWQPSVLLDLDLITAGLPVPEH  
SPDAQRCEILCNVTKKCDINKEFTDLDLQVAKETGSEVADFTVADRAIHSRL  
SKOSISTREKLVLTITDFOKALRGFLPASAISVNLKPRDLGMDKIGLHVRQIAD  
TIOIPAVCLKKEKPELPANLPIROGTGILYGPETGKTLAGVYARSRMFTISV  
KPEPLKXYIGASQAVADFIIRNOAKPCITFEDEESIAPRGHNGVTVDVWVO  
LTPDQVEGIGQVYVAATSRPDLIPALRGRLDKCYCPPODVTSTYSEKQ  
OMLHSPVSRLENTNTSDSLPIADVDLOHVASVYDSFGADIKALLIYNOALALNG  
MLSKMETIPDESKFMVRLYFGSSSTESLGGTSSDSSQCSASASTODIPGP  
GKDLFSPVPLFTASQGCQELTQEQRLQADISITIKGRYRSQSEDESMNOPGPI  
K\*RLAISQSHLMTALGHTRPISIDPDWKNFAEL"  
complement(4948..5130)  
/rpt\_family="ALU"  
complement(6581..7133)  
/rpt\_family="L1"  
complement(7767..8037)  
/rpt\_family="ALU"  
complement(8186..8472)  
/rpt\_family="ALU"  
8473..8625  
/gene="WUGSC:H\_RG083M05.1"  
/note="match to human 3' EST H75782 (NID:g1049794), bases  
287-444"  
8841..9161  
/gene="WUGSC:H\_RG083M05.1"  
/note="match to human 5' EST H75921 (NID:g1050050), bases  
21-348"  
9481..9547  
/gene="WUGSC:H\_RG083M05.1"  
/note="match to human 5' EST N22627 (NID:g1130501), bases  
276-343"  
complement(12612..12907)  
/rpt\_family="ALU"  
13670..13793  
/gene="WUGSC:H\_RG083M05.1"  
/note="match to human 5' EST H41382 (NID:917434), bases  
143-266"  
13794..13877  
/rpt\_family="ALU"  
13878..13906  
/gene="WUGSC:H\_RG083M05.1"  
/note="match to human 5' EST H41382 (NID:917434), bases  
30-58"

repeat\_region  
13907..14104  
/rpt\_family="ALU"  
complement(14110..14137)  
/rpt\_family="L1"  
complement(15618..15907)  
/rpt\_family="ALU"  
17227..17522  
/rpt\_family="ALU"  
18667..19235  
/note="match to human fetal brain 5' EST D61494  
(NID:g970409), bases 1-255, and to human 3' EST R07476  
(NID:g759399)"  
19350..19670  
/rpt\_family="ALU"  
21507..37303  
/note="similarity to various SS-RNA virus polyproteins;  
pseudogene; region of matches and close matches to  
multiple human ESTs, see R08740 (NID:g842257)"

repeat\_region  
13907..14104  
/rpt\_family="ALU"  
complement(14110..14137)  
/rpt\_family="L1"  
complement(15618..15907)  
/rpt\_family="ALU"  
17227..17522  
/rpt\_family="ALU"  
18667..19235  
/note="match to human fetal brain 5' EST D61494  
(NID:g970409), bases 1-255, and to human 3' EST R07476  
(NID:g759399)"  
19350..19670  
/rpt\_family="ALU"  
21507..37303  
/note="similarity to various SS-RNA virus polyproteins;  
pseudogene; region of matches and close matches to  
multiple human ESTs, see R08740 (NID:g842257)"

repeat\_region  
13907..14104  
/rpt\_family="ALU"  
complement(14110..14137)  
/rpt\_family="L1"  
complement(15618..15907)  
/rpt\_family="ALU"  
17227..17522  
/rpt\_family="ALU"  
18667..19235  
/note="match to human fetal brain 5' EST D61494  
(NID:g970409), bases 1-255, and to human 3' EST R07476  
(NID:g759399)"  
19350..19670  
/rpt\_family="ALU"  
21507..37303  
/note="similarity to various SS-RNA virus polyproteins;  
pseudogene; region of matches and close matches to  
multiple human ESTs, see R08740 (NID:g842257)"

repeat\_region  
13907..14104  
/rpt\_family="ALU"  
complement(14110..14137)  
/rpt\_family="L1"  
complement(15618..15907)  
/rpt\_family="ALU"  
17227..17522  
/rpt\_family="ALU"  
18667..19235  
/note="match to human fetal brain 5' EST D61494  
(NID:g970409), bases 1-255, and to human 3' EST R07476  
(NID:g759399)"  
19350..19670  
/rpt\_family="ALU"  
21507..37303  
/note="similarity to various SS-RNA virus polyproteins;  
pseudogene; region of matches and close matches to  
multiple human ESTs, see R08740 (NID:g842257)"

repeat\_region  
13907..14104  
/rpt\_family="ALU"  
complement(14110..14137)  
/rpt\_family="L1"  
complement(15618..15907)  
/rpt\_family="ALU"  
17227..17522  
/rpt\_family="ALU"  
18667..19235  
/note="match to human fetal brain 5' EST D61494  
(NID:g970409), bases 1-255, and to human 3' EST R07476  
(NID:g759399)"  
19350..19670  
/rpt\_family="ALU"  
21507..37303  
/note="similarity to various SS-RNA virus polyproteins;  
pseudogene; region of matches and close matches to  
multiple human ESTs, see R08740 (NID:g842257)"



QY 1084 tagagatcttctaagggaaccccccacttacttgcacacccatgcccgaactg 1143  
Db 36034 TAGGAGTCTTCTTAAGGGAACCCCACTTACTGCCACACCATATAGCCCCGCAACTG 36093  
QY 1144 ctataccctgccaactcttgcatagcataaataactatatttggaaaggaataatgat 1203  
Db 36094 CTATACACTGCGCACTCTTTCATGCATGCAATGCAATATCTATTTGGAGAGAAAATGAT 36153  
QY 1204 taatccctagttgctctggaagacttggatgacatgctgtgttggaacttaccaccaac 1263  
Db 36154 TAACTCTAGTTGCTCTGGAAGGACTTGGAGTCACTGTCTGTTGGACTTACTTACCCCAAC 36213  
QY 1264 tggatagtcgtatgggggtggagttcaagatcaggcaagagaataatgtaaaagagt 1323  
Db 36214 TGGTATGCTCTATGGGGGTGGAGTTCAAGATCAGGCAAGAGAAAATGTAAGAGAGT 36273  
QY 1324 aatctcccaactcaaccgggtacatggcaacttagccctacaaaggaactagatcctc 1383  
Db 36274 AATCTCCCACTCAACCGGGGTACATGGCACACTTACGCCCTACAAAGAGACTAGATCTCTC 36333  
QY 1384 aaactacatgaacccctccgtaaccatctgcgctgtgtaagcctattataaccct 1443  
Db 36334 AAAACTACATGTAACCCCTCGTACCCATACCTGCTGTAAAGCCTATTATACCACTC 36393  
QY 1444 caactggctccatgaggtctcgagcccaaaacccactaactgttggatgctccctcc 1503  
Db 36394 CACTGGGCTCCATAGGCTCTGGGCCAAACCCCTACATGTTGGTATGGCTCCCTCCCT 36453  
QY 1504 gaacttaaggccatagttctcaatccctgtactgaaacaaaggaaactcagacaga 1563  
Db 36454 GAACCTTAGGCCATATGTTCAATCCCTGTACCTGAAACAAATGGAAACACTTCAGCAAGA 36513  
QY 1564 aataaacacacatccgcttttagtagaacctctgttccaatcctggaaataacccatc 1623  
Db 36514 AATTAACACCACTTCCCTTTTAAAGGACCTCTTGTTCATCTGGAAATTAACCCATAC 36573  
QY 1624 ctcaaacctcaactgtgttaaaatttagcaatctactacacaaacaccccaatgat 1683  
Db 36574 CTCAAACCTCACTGCTTAATAATTAGCAATCTACTATACACAACTCCCAATGCAAT 36633  
QY 1684 caagtggtgtaactctcccaacaaatagctctgactaacctcaggaatatttctgtc 1743  
Db 36634 CAGGTGGGTAACTCTCCACACAAATAGTGTGCTACCTCAGGAATATTTTGTGCTG 36693  
QY 1744 tggtaactgagcctatcgttggtaagtgctctcaagaactatgttctcctcatt 1803  
Db 36694 TGGTACTCTAGCTATCTGTTGTAATGGCTCTCAGAACTATGTGCTTCTCTCAT 36753  
QY 1804 cttagtgcccccatagaccatactcaactgaagaattatagatgatactatctaa 1863  
Db 36754 CTTAGTGGCCCCCTATGACCATCTACACTGAAACAAATTTATACAGTTATGTCATATCTAA 36813  
QY 1864 gcccgcaacaaagaagtaaccatctccttctgtatagagcaggaagtgttagtgc 1923  
Db 36814 GCCCGCAACAAAGAAGTACCCTCTCTTCTTGTATAGAGCAAGAGTGTAGTGC 36873  
QY 1924 actaggtactgagatgggtgatacaaaccttactcaagttactactacaactatctca 1983  
Db 36874 ACTAGGTACTGGCATTTGGGGATCAACAACTCTACTCAGTTCTACTACAAACTATCTCA 36933  
QY 1984 agaaccaaatggagacatgaaaggggtgcggagctccctggtcacttgcaagataact 2043  
Db 36934 AGAACCTAAATGGGAGATGGAACGGGTGCGCGACTCCCTGGTCACTTGCANAGATCACT 36993  
QY 2044 taactccctagcagcagtagtctctcaaaatcgaagactttagacttgtaacgcgtga 2103  
Db 36994 TAACTCCCTAGCAGAGTAGTCTTCAAAATGCAAGAGCTTGAAGCTTCTTAACCGCTGA 37053  
QY 2104 aagagggggaacctgttattttaggggaagaatgctgtatlatatgtaataacacgg 2163  
Db 37054 AAGAGGGGGAACCTGTTATTTTAAAGGGAAGATGCTGTATATGTAAATCAATCCGG 37113

QY 2164 aatcgtaactgagaaggttaagaanaattcgagatcgataatacaacgttagagcagagact 2223  
Db 37114 AATCGTACCTGAGAGAAATTAAGAATTCAGATCAATTCACAGTAAAGACAGAGAGCT 37173  
QY 2224 tcgaacactggagccctgggggctctccagccaaatgtagtgcctggaattccctctt 2283  
Db 37174 TCGAAACACTGGAACCTGGGGCTCCCTCAGCCAAATGGAATGCCCTGGAATCTCCCTCTCT 37233  
QY 2284 aggaacttagcagctataatattgtactccctcttggaaacctgtaattcttactcc 2343  
Db 37234 AGGACCTTAGAGCAGCTATATATGCTACTCCTCTTGGACCTGTATCTTTAACTCTCT 37293  
QY 2344 tgttaactgtctcttccagaatcgaagctgttaaaactaacaatggagcccaagatga 2403  
Db 37294 TGTTAACCTGTCTCTCCAGAAATCGAAGCTGTAATAAATGGAAGCCCAAGATGCA 37353  
QY 2404 gtccaagaactaagatctaccggaagacccttggacgggctgttagccagatctgagt 2463  
Db 37354 GTCCAAAGACTAAGATCTTACCGCAGACCCCTGGACCGGCTGTAGCCCAAGATGATG 37413  
QY 2464 taatgacatcaaaaggacccctccctgaggaatctcagctgacaaaccttactaagccc 2523  
Db 37414 TAATGACATCAAAAGGACACCCCTCCTAGGAAATCTAGCTGCAACAACTCTTACGCCC 37473  
QY 2524 caattcagcaggaagcagtttagagcgtc-tcggccaacctccccaacagcaactaggt 2582  
Db 37474 CAATTAGCAGGAAGCAGTTAGAGCGGTGCGGCAACTCCGCCAAGCAACTATGATT 37533  
QY 2583 ttccgttgagatggg 2599  
Db 37534 TTCCGTGTAAGATGGGG 37550